| scholarly article | Q13442814 |
| P50 | author | Justin A Clark | Q99580008 |
| P2093 | author name string | David S Burgess | |
| P2860 | cites work | A Phase 1 Study of Intravenous Plazomicin in Healthy Adults to Assess Potential Effects on the QT/QTc Interval, Safety, and Pharmacokinetics | Q91075988 |
| In vitro activity of Plazomicin against Enterobacteriaceae isolates carrying genes encoding aminoglycoside-modifying enzymes most common in US Census divisions | Q91129240 | ||
| Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes and other resistance mechanisms | Q91467924 | ||
| Application of the Hartford Hospital Nomogram for Plazomicin Dosing Interval Selection in Patients with Complicated Urinary Tract Infection | Q92264455 | ||
| A Simulated Application of the Hartford Hospital Aminoglycoside Dosing Nomogram for Plazomicin Dosing Interval Selection in Patients With Serious Infections Caused by Carbapenem-Resistant Enterobacterales | Q93085087 | ||
| Evaluation of Plazomicin, Tigecycline, and Meropenem Pharmacodynamic Exposure against Carbapenem-Resistant Enterobacteriaceae in Patients with Bloodstream Infection or Hospital-Acquired/Ventilator-Associated Pneumonia from the CARE Study (ACHN-490-0 | Q93119291 | ||
| Will 10 Million People Die a Year due to Antimicrobial Resistance by 2050? | Q28033223 | ||
| The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace. | Q30234957 | ||
| Aminoglycosides: activity and resistance | Q33548221 | ||
| Emergence of Ceftazidime-Avibactam Resistance and Restoration of Carbapenem Susceptibility in Klebsiella pneumoniae Carbapenemase-Producing K pneumoniae: A Case Report and Review of Literature | Q33862098 | ||
| Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents. | Q34058006 | ||
| Synthesis and spectrum of the neoglycoside ACHN-490 | Q34134992 | ||
| Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates | Q34625178 | ||
| Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects | Q34632230 | ||
| Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece | Q36107990 | ||
| Mechanisms of Resistance to Aminoglycoside Antibiotics: Overview and Perspectives | Q36575916 | ||
| Back to the future: using aminoglycosides again and how to dose them optimally | Q36916092 | ||
| Aminoglycoside Resistance: The Emergence of Acquired 16S Ribosomal RNA Methyltransferases | Q36930694 | ||
| In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012. | Q37712980 | ||
| Evaluating the Clinical Burden and Mortality Attributable to Antibiotic Resistance: The Disparity of Empirical Data and Simple Model Estimations | Q38599622 | ||
| Potential impact of a microarray-based nucleic acid assay for rapid detection of Gram-negative bacteria and resistance markers in positive blood cultures. | Q38853173 | ||
| Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance | Q39828366 | ||
| Kill kinetics and regrowth patterns of Escherichia coli exposed to gentamicin concentration-time profiles simulating in vivo bolus and infusion dosing | Q39865745 | ||
| Rapid Aminoglycoside NP Test for Rapid Detection of Multiple Aminoglycoside Resistance in Enterobacteriaceae | Q41646813 | ||
| Activity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia coli and Klebsiella pneumoniae from New York City | Q42953415 | ||
| Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration | Q44483617 | ||
| Antimicrobial activity of plazomicin against Enterobacteriaceae-producing carbapenemases from 50 Brazilian medical centers | Q46244641 | ||
| Efficacy and Safety of Plazomicin Compared with Levofloxacin in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis: A Multicenter, Randomized, Double-Blind, Phase 2 Study | Q49598865 | ||
| High prevalence of 16S rRNA methyltransferases among carbapenemase-producing Enterobacteriaceae in the UK & Ireland. | Q53700318 | ||
| Plazomicin Retains Antibiotic Activity against Most Aminoglycoside Modifying Enzymes. | Q54205904 | ||
| A Phase 1 Study to Assess the Pharmacokinetics of Intravenous Plazomicin in Adult Subjects with Varying Degrees of Renal Function | Q57052024 | ||
| Antimicrobial Resistance: Pharmacokinetics‐Pharmacodynamics of Antimicrobial Therapy: It’s Not Just for Mice Anymore | Q58033538 | ||
| Activity of Plazomicin against Gram-negative and Gram-positive Bacterial Pathogens Isolated from Patients in Canadian Hospitals from 2013 to 2017: CANWARD Surveillance Study | Q58100679 | ||
| Reappraisal of Contemporary Pharmacokinetic and Pharmacodynamic Principles for Informing Aminoglycoside Dosing | Q58600954 | ||
| Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae | Q62065975 | ||
| Once-Daily Plazomicin for Complicated Urinary Tract Infections | Q62065976 | ||
| Plazomicin Is Active Against Metallo-β-Lactamase-Producing Enterobacteriaceae | Q64104827 | ||
| In Vivo Efficacy of Plazomicin Alone or in Combination with Meropenem or Tigecycline against Enterobacteriaceae Isolates Exhibiting Various Resistance Mechanisms in an Immunocompetent Murine Septicemia Model. | Q64894751 | ||
| Antimicrobial activity of a novel aminoglycoside, ACHN-490, against Acinetobacter baumannii and Pseudomonas aeruginosa from New York City | Q82736865 | ||
| In Vitro Activity of Plazomicin against Gram-Negative and Gram-Positive Isolates Collected from U.S. Hospitals and Comparative Activities of Aminoglycosides against Carbapenem-Resistant Enterobacteriaceae and Isolates Carrying Carbapenemase Genes | Q88984613 | ||
| Evaluation of the Bactericidal Activity of Plazomicin and Comparators against Multidrug-Resistant Enterobacteriaceae | Q88984656 | ||
| The GenMark ePlex®: another weapon in the syndromic arsenal for infection diagnosis | Q90473032 | ||
| No Effect of Plazomicin on the Pharmacokinetics of Metformin in Healthy Subjects | Q90863550 | ||
| Frequency of 16S ribosomal RNA methyltransferase detection among Escherichia coli and Klebsiella pneumoniae clinical isolates obtained from patients in Canadian hospitals (CANWARD, 2013-2017) | Q91027069 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | plazomicin | Q15426988 |
| P304 | page(s) | 2049936120952604 | |
| P577 | publication date | 2020-01-01 | |
| P1433 | published in | Therapeutic advances in infectious disease | Q26842293 |
| P1476 | title | Plazomicin: a new aminoglycoside in the fight against antimicrobial resistance | |
| P478 | volume | 7 |
Search more.